Physician profile
James D Bryan
NPI 1962449934
$705.49
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $11.68 · 2021: $24.87.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.34 | 2019 | |
| Astellas Pharma US INC | $97.83 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $63.00 | 2019 | |
| Abbott Laboratories | $51.08 | 2019-2021 | |
| Glaxosmithkline, LLC. | $50.90 | 2019 | |
| Amgen INC. | $41.67 | 2019 | |
| Pfizer INC. | $38.25 | 2019 | |
| Sanofi-Aventis U.S. LLC | $36.74 | 2019 | |
| Janssen Pharmaceuticals, INC | $35.18 | 2019 | |
| Aytu Biopharma, INC. | $20.00 | 2019 | |
| Merck Sharp & Dohme LLC | $19.93 | 2019 | |
| Melinta Therapeutics, LLC | $17.72 | 2019 | |
| Novo Nordisk INC | $15.17 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.16 | 2019 | |
| Abbvie INC. | $14.97 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $14.57 | 2019 | |
| Genentech USA, INC. | $14.21 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $12.79 | 2019 | |
| Amarin Pharma, INC. | $12.44 | 2019 | |
| Daiichi Sankyo INC. | $11.68 | 2020 | |
| Lilly USA, LLC | $10.86 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.